Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders

NCT02065869 is registered in ClinicalTrials.gov with Bellicum Pharmaceuticals as lead sponsor.

NCT NCT02065869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02065869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of CaspaCIDe T Cells (BPX-501; Rivogenlecleucel) From an HLA Partially Matched Family Donor After Negative Selection of TCRαβ+ T Cells in Paediatric Patients Affected by Haematological Disorders
Lead sponsor
Bellicum Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2014
Completion date
September 7, 2021
Enrollment
187 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, anemia, aplastic, anemia, sickle cell, cytopenia, diamond blackfan anemia, fanconi anemia, hemoglobinopathies, leukemia, acute myeloid (aml), child, lymphoma, non-hodgkin, myelodysplastic syndrome, osteopetrosis, primary immunodeficiency, thalassemia